Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All bamlanivimab/etesevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Emergence of SARS-CoV-2 Spike Escape Mutation Q493r After Bamlanivimab/Etesevimab Treatment for COVID-19

Focosi et al., Research Square, doi:10.21203/rs.3.rs-524959/v1
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
21st treatment shown to reduce risk in May 2021
 
*, now with p = 0.00036 from 21 studies, recognized in 7 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Case study showing that a mutation resistant to both bamlanivimab and etesevimab can arise in vivo. Authors note that accelerated evolution can occur under selective pressure from therapeutic interventions with neutralizing antibodies, and that bamlanivimab was withdrawn as a monotherapy because of failure against E484K-positive SARS-CoV-2 variants.
Focosi et al., 18 May 2021, preprint, 7 authors.
This PaperBamlaniv../e..All
Emergence of SARS-CoV-2 Spike Escape Mutation Q493r After Bamlanivimab/Etesevimab Treatment for COVID-19
Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla Gasperina, Andreina Baj, Fabrizio Maggi
doi:10.21203/rs.3.rs-524959/v1
SARS-CoV-2 variants are usually a consequence of random mutations in humans or other hosts, but accelerated evolution can also occur under selective pressure from therapeutic interventions with neutralizing antibodies1. Bamlanivimab has been recently withdrawn from the vendor as a monotherapy because of failure against E484K-positive SARS-CoV-2 variants, but emergency use authorization remains in place for the bamlanivimab/etesevimab cocktail2, for which no completely resistant variant has been reported to date. We report here the rst in vivo case of a Spike escape mutation conferring combined resistance to both bamlanivimab and etesevimab.
Declarations We declare we have no con ict of interest related to this manuscript.
References
Chen, Zody, Mediavilla, Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment
Ortega, Pujol, Jastrzebska, Rangel, Mutations in the SARS-CoV-2 spike protein modulate the virus a nity to the human ACE2 receptor, an in silico analysis, EXCLI journal
Starr, Greaney, Dingens, Bloom, Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016, Cel Reports Medicine
Weisblum, Schmidt, Zhang, Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants, eLife
{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2024, 3, 3]], 'date-time': '2024-03-03T13:52:57Z', 'timestamp': 1709473977616}, 'posted': {'date-parts': [[2021, 5, 17]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2021, 5, 17]], 'date-time': '2021-05-17T00:00:00Z', 'timestamp': 1621209600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 5, 14]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>SARS-CoV-2 variants are usually a consequence of random mutations in humans ' 'or other hosts, but accelerated evolution can also occur under selective pressure from ' 'therapeutic interventions with neutralizing antibodies1. Bamlanivimab has been recently ' 'withdrawn from the vendor as a monotherapy because of failure against E484K-positive ' 'SARS-CoV-2 variants, but emergency use authorization remains in place for the ' 'bamlanivimab/etesevimab cocktail2, for which no completely resistant variant has been ' 'reported to date. We report here the first <jats:italic>in vivo</jats:italic> case of a Spike ' 'escape mutation conferring combined resistance to both bamlanivimab and etesevimab.</jats:p>', 'DOI': '10.21203/rs.3.rs-524959/v1', 'type': 'posted-content', 'created': {'date-parts': [[2021, 5, 17]], 'date-time': '2021-05-17T13:39:52Z', 'timestamp': 1621258792000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Emergence of SARS-CoV-2 Spike Escape Mutation Q493r After Bamlanivimab/Etesevimab Treatment for ' 'COVID-19', 'prefix': '10.21203', 'author': [ { 'given': 'Daniele', 'family': 'Focosi', 'sequence': 'first', 'affiliation': [ { 'name': 'North-Western Tuscany Blood Bank, Pisa University Hospital, ' 'Pisa, Italy'}]}, { 'given': 'Federica', 'family': 'Novazzi', 'sequence': 'additional', 'affiliation': [{'name': 'Laboratory of Microbiology, ASST Sette Laghi, Varese, Italy'}]}, { 'given': 'Angelo', 'family': 'Genoni', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Insubria, ' 'Varese, Italy'}]}, { 'given': 'Francesco', 'family': 'Dentali', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Insubria, ' 'Varese, Italy'}]}, { 'given': 'Daniela Dalla', 'family': 'gasperina', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Insubria, ' 'Varese, Italy'}]}, { 'ORCID': 'http://orcid.org/0000-0003-0088-2712', 'authenticated-orcid': False, 'given': 'Andreina', 'family': 'Baj', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Insubria, ' 'Varese, Italy'}]}, { 'given': 'Fabrizio', 'family': 'Maggi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Insubria, ' 'Varese, Italy'}]}], 'member': '8761', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-524959/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-524959/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 7, 29]], 'date-time': '2022-07-29T02:01:04Z', 'timestamp': 1659060064000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-524959/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 5, 17]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-524959/v1', 'relation': { 'is-preprint-of': [ { 'id-type': 'doi', 'id': '10.3201/eid2710.211538', 'asserted-by': 'subject'}]}, 'subject': [], 'published': {'date-parts': [[2021, 5, 17]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit